Publikationen, an denen er mitarbeitet José Antonio Páramo Fernández (20)

2022

  1. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

2019

  1. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  2. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

2018

  1. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

2013

  1. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients

    Thrombosis and Haemostasis, Vol. 110, Núm. 1, pp. 184-190

2003

  1. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9

    Thrombosis and Haemostasis

2002

  1. Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells

    Thrombosis and Haemostasis, Vol. 88, Núm. 6, pp. 1060-1065

2001

  1. Protocolo diagnóstico y terapéutico de la diátesis trombótica

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 53, pp. 2855-2858

  2. Tratamiento anticoagulante

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 53, pp. 2832-2843

1999

  1. Effect of the administration of recombinant hirudin and/or tissue- plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits

    British Journal of Haematology, Vol. 105, Núm. 1, pp. 117-121

  2. Effects of low molecular weight heparin, alone or combined with antithrombin III, on mortality, fibrin deposits and hemostatic parameters in endotoxin-induced disseminated intravascular coagulation in rabbits

    American Journal of Hematology, Vol. 60, Núm. 1, pp. 6-11

1998

  1. Endotoxin-induced disseminated intravascular coagulation in rabbits: Effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality

    Journal of Laboratory and Clinical Medicine, Vol. 131, Núm. 1, pp. 77-83

  2. Infusion of anti-PAI-1 monoclonal antibodies to rabbits given endotoxin to induce DIG

    Fibrinolysis and Proteolysis, Vol. 12, Núm. SUPPL. 1, pp. 6

1996

  1. Aprotinina en el control de las hemorragias en cirugía

    Medicina Clinica, Vol. 106, Núm. 8, pp. 307-316

  2. Contribution of cytokines to hyperf ibrinolysis during orthotopic liver transplantation and effect of aprotinin

    Fibrinolysis, Vol. 10, Núm. 5-6, pp. 325-329

  3. Different fibrinolytic profile in orthopedic and abdominal surgery

    Fibrinolysis, Vol. 10, Núm. SUPPL. 3, pp. 132

  4. Hirudin improves hbrinolysis and mortality in endotoxin-induced intravascular coagulation in rabbits

    Fibrinolysis, Vol. 10, Núm. SUPPL. 3, pp. 72

1995

  1. Plasma thrombomodulin is increased in cord blood of healthy newborns [2]

    Thrombosis and Haemostasis